» Articles » PMID: 36231127

Investigating Two Modes of Cancer-Associated Antigen Heterogeneity in an Agent-Based Model of Chimeric Antigen Receptor T-Cell Therapy

Overview
Journal Cells
Publisher MDPI
Date 2022 Oct 14
PMID 36231127
Authors
Affiliations
Soon will be listed here.
Abstract

Chimeric antigen receptor (CAR) T-cell therapy has been successful in treating liquid tumors but has had limited success in solid tumors. This work examines unanswered questions regarding CAR T-cell therapy using computational modeling, such as, what percentage of the tumor must express cancer-associated antigens for treatment to be successful? The model includes cancer cell and vascular and CAR T-cell modules that interact with each other. We compare two different models of antigen expression on tumor cells, binary (in which cancer cells are either susceptible or are immune to CAR T-cell therapy) and gradated (where each cancer cell has a probability of being killed by a CAR T-cell). We vary the antigen expression levels within the tumor and determine how effective each treatment is for the two models. The simulations show that the gradated antigen model eliminates the tumor under more parameter values than the binary model. Under both models, shielding, in which the low/non-antigen-expressing cells protect high antigen-expressing cells, reduced the efficacy of CAR T-cell therapy. One prediction is that a combination of CAR T-cell therapies that targets the general population of cells as well as one that specifically targets cancer stem cells should increase its efficacy.

Citing Articles

In silico study of heterogeneous tumour-derived organoid response to CAR T-cell therapy.

Luque L, Carlevaro C, Rodriguez-Lomba E, Lomba E Sci Rep. 2024; 14(1):12307.

PMID: 38811838 PMC: 11137006. DOI: 10.1038/s41598-024-63125-5.


Mathematical Modeling Support for Lung Cancer Therapy-A Short Review.

Smieja J Int J Mol Sci. 2023; 24(19).

PMID: 37833963 PMC: 10572824. DOI: 10.3390/ijms241914516.


From barriers to novel strategies: smarter CAR T therapy hits hard to tumors.

Khawar M, Ge F, Afzal A, Sun H Front Immunol. 2023; 14:1203230.

PMID: 37520522 PMC: 10375020. DOI: 10.3389/fimmu.2023.1203230.

References
1.
Alhabbab R . Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. Front Genet. 2020; 11:312. PMC: 7188929. DOI: 10.3389/fgene.2020.00312. View

2.
Harris T, Banigan E, Christian D, Konradt C, Tait Wojno E, Norose K . Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells. Nature. 2012; 486(7404):545-8. PMC: 3387349. DOI: 10.1038/nature11098. View

3.
Feins S, Kong W, Williams E, Milone M, Fraietta J . An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019; 94(S1):S3-S9. DOI: 10.1002/ajh.25418. View

4.
Tchou J, Wang L, Selven B, Zhang H, Conejo-Garcia J, Borghaei H . Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012; 133(2):799-804. PMC: 4964602. DOI: 10.1007/s10549-012-2018-4. View

5.
Norton K, Popel A . Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis. Sci Rep. 2016; 6:36992. PMC: 5107954. DOI: 10.1038/srep36992. View